We would envision a series of white papers with recommendations for standardized sepsis models. These standardized sepsis models represent an important initial stage of increasing the reproducibility of sepsis science, leading to the development and implementation of better therapies to address this lethal disease.
1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K. International Forum of Acute Care TrialistsAssessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med
2016; 193 3:259–272.
2. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med
2014; 42 3:625–631.
3. Sjoding MW, Prescott HC, Wunsch H, Iwashyna TJ, Cooke CR. Longitudinal changes in ICU admissions among elderly patients in the United States. Crit Care Med
2016; 44 7:1353–1360.
4. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, Lemeshow S, Osborn T, Terry KM, Levy MM. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med
5. Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: Propensity matched cohort study. BMJ
6. Odden AJ, Rohde JM, Bonham C, Kuhn L, Malani PN, Chen LM, Flanders SA, Iwashyna TJ. Functional outcomes of general medical patients with severe sepsis. BMC Infect Dis
7. Prescott HC, Langa KM, Liu V, Escobar GJ, Iwashyna TJ. Increased 1-year healthcare use in survivors of severe sepsis. Am J Respir Crit Care Med
2014; 190 1:62–69.
8. Headley P, Russell C. A magic bullet for sepsis—a needle in a haystack or barking up the wrong tree. Surgery
2015; 33 11:521–527.
9. England L, Fu L, Miller S. Checklist manifesto for electronic resources: getting ready for the fiscal year and beyond. J Electron Resources Librarianship
2011; 23 4:307–326.
10. Duff P. A simple checklist for preventing major complications associated with cesarean delivery. Obstet Gynecol
2010; 116 6:1393–1396.
11. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, Macleod MR. Can animal models
of disease reliably inform human studies? PLoS Med
2010; 7 3:e1000245.
12. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models
of type 1 diabetes. Nat Rev Immunol
2004; 4 12:989–997.
13. Lapinlampi N, Melin E, Aronica E, Bankstahl JP, Becker A, Bernard C, Gorter JA, Gröhn O, Lipsanen A, Lukasiuk K, et al. Common data elements and data management: remedy to cure underpowered preclinical studies. Epilepsy Res
14. Vahidy F, Schabitz WR, Fisher M, Aronowski J. Reporting standards for preclinical studies of stroke therapy. Stroke
2016; 47 10:2435–2438.
15. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, Barnwell JW, Turner G. Langhorne J and participants of the Hinxton Retreat meeting on Animal Models
for Research on Severe MThe role of animal models
for research on severe malaria. PLoS Pathog
2012; 8 2:e1002401.
16. King A, Bowe J. Animal models
for diabetes: Understanding the pathogenesis and finding new treatments. Biochem Pharmacol
17. Auer JA, Goodship A, Arnoczky S, Pearce S, Price J, Claes L, von Rechenberg B, Hofmann-Amtenbrinck M, Schneider E, Müller-Terpitz R, et al. Refining animal models
in fracture research: seeking consensus in optimising both animal welfare and scientific validity for appropriate biomedical use. BMC Musculoskelet Disord
18. Rice AS, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, Preclinical Pain C, Mogil JS, Stohr T. Animal models
and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain
2008; 139 2:243–247.
19. Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin
2012; 33 2:173–181.
20. Getz GS, Reardon CA. Animal models
of atherosclerosis. Arterioscler Thromb Vasc Biol
21. Joffe AR, Bara M, Anton N, Nobis N. Expectations for methodology and translation of animal research: a survey of health care workers. BMC Med Ethics
22. Bara M, Joffe AR. The methodological quality of animal research in critical care: the public face of science. Ann Intensive Care
23. Ramirez FD, Motazedian P, Jung RG, Di Santo P, MacDonald ZD, Moreland R, Simard T, Clancy AA, Russo JJ, Welch VA, et al. Methodological rigor in preclinical cardiovascular studies: targets to enhance reproducibility
and promote research translation. Circ Res
24. Minnerup J, Zentsch V, Schmidt A, Fisher M, Schabitz WR. Methodological quality of experimental stroke studies published in the stroke journal: time trends and effect of the basic science checklist. Stroke
2016; 47 1:267–272.
25. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today
2006; 11 (7–8):355–363.
26. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility
2014; 505 7485:612–613.
27. Hsieh T, Vaickus MH, Remick DG. Enhancing scientific foundations to ensure reproducibility
: a new paradigm. Am J Pathol
2018; 188 1:6–10.
28. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA
2006; 296 14:1731–1732.
29. Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, Azevedo LC, Bahrami S, Boros M, Cooney R, et al. Abandon the mouse research ship? Not just yet! Shock
2014; 41 6:463–475.
30. Idris AH, Becker LB, Ornato JP, Hedges JR, Bircher NG, Chandra NC, Cummins RO, Dick W, Ebmeyer U, Halperin HR, et al. Utstein-style guidelines
for uniform reporting of laboratory CPR research. A statement for healthcare professionals from a task force of the American Heart Association, the American College of Emergency Physicians, the American College of Cardiology, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Institute of Critical Care Medicine, the Safar Center for Resuscitation Research, and the Society for Academic Emergency Medicine. Writing Group. Circulation
1996; 94 9:2324–2336.
31. Idris AH, Becker LB, Wenzel V, Fuerst RS, Gravenstein N. Lack of uniform definitions and reporting in laboratory models of cardiac arrest: a review of the literature and a proposal for guidelines
. Ann Emerg Med
1994; 23 1:9–16.
32. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models
, disease mechanisms and therapeutic opportunities. J Intern Med
2007; 261 1:17–31.
33. Ortiz A, Sanchez-Niño MD, Izquierdo MC, Martin-Cleary C, Garcia-Bermejo L, Moreno JA, Ruiz-Ortega M, Draibe J, Cruzado JM, Garcia-Gonzalez MA, et al. Translational value of animal models
of kidney failure. Eur J Pharmacol
34. Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris)
2015; 63 3:136–143.
35. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood
2015; 125 21:3253–3262.
36. Zhang L, Qiu W, Crooke S, Li Y, Abid A, Xu B, Finn MG, Lin F. Development of autologous C5 vaccine nanoparticles to reduce intravascular hemolysis in vivo. ACS Chem Biol
2017; 12 2:539–547.
37. Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, Kramer E, Becker L, Robertson C, Koster R, Zaritsky A, et al. Recommended guidelines
for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital ’Utstein style’. American Heart Association. Circulation
1997; 95 8:2213–2239.
38. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A
2013; 110 9:3507–3512.
39. Remick D. Use of animal models
for the study of human disease-a shock society debate. Shock
2013; 40 4:345–346.
40. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock
1995; 4 2:89–95.
41. Moskowitz A, Omar Y, Chase M, Lokhandwala S, Patel P, Andersen LW, Cocchi MN, Donnino MW. Reasons for death in patients with sepsis and septic shock. J Crit Care
42. Osuchowski MF, Connett J, Welch K, Granger J, Remick DG. Stratification is the key: Inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med
43. Dyson A, Singer M. Animal models
of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med
2009; 37 (1 suppl):S30–S37.
44. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res
45. Chang R, Holcomb JB, Johansson PI, Pati S, Schreiber MA, Wade CE. Plasma resuscitation improved survival in a cecal ligation and puncture rat model of sepsis. Shock
46. Csoka B, Németh ZH, Mukhopadhyay P, Spolarics Z, Rajesh M, Federici S, Deitch EA, Bátkai S, Pacher P, Haskó G. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One
2009; 4 7:e6409.
47. Tschop J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, Dattilo J, Lentsch AB, Tschöp MH, Caldwell CC. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol
2009; 183 1:499–505.
48. Benjamim CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J Immunol
2005; 174 3:1616–1620.
49. Rios-Santos F, Benjamim CF, Zavery D, Ferreira SH, Cunha Fde Q. A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligaton and puncture sepsis. Shock
2003; 19 1:61–65.
50. Nullens S, Staessens M, Peleman C, Plaeke P, Malhotra-Kumar S, Francque S, De Man JG, De Winter BY. Beneficial effects of anti-interleukin-6 antibodies on impaired gastrointestinal motility, inflammation and increased colonic permeability in a murine model of sepsis are most pronounced when administered in a preventive setup. PLoS One
2016; 11 4:e0152914.
51. Vyas D, Javadi P, Dipasco PJ, Buchman TG, Hotchkiss RS, Coopersmith CM. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol
2005; 289 4:R1048–R1053.
52. Ozer EK, Goktas MT, Kilinc I, Bariskaner H, Ugurluoglu C, Iskit AB. Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats. Biomed Pharmacother
53. Fredenburgh LE, Velandia MM, Ma J, Olszak T, Cernadas M, Englert JA, Chung SW, Liu X, Begay C, Padera RF, et al. Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. J Immunol
2011; 187 10:5255–5267.
54. Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukashev D, Buras JA, Remick DG, Sitkovsky M. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol
2011; 186 4:2444–2453.
55. Csoka B, Németh ZH, Mukhopadhyay P, Spolarics Z, Rajesh M, Federici S, Deitch EA, Bátkai S, Pacher P, Haskó G. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol
2010; 185 1:542–550.
56. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med
2002; 166 9:1197–1205.
57. Alverdy JC, Krezalek MA. Collapse of the microbiome, emergence of the pathobiome, and the immunopathology of sepsis. Crit Care Med
58. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH. Cecal ligation and puncture. Shock
2005; 24 (suppl 1):52–57.
59. Wu R, Dong W, Zhou M, Zhang F, Marini CP, Ravikumar TS, Wang P. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med
2007; 176 8:805–813.
60. Iskander KN, Vaickus M, Duffy ER, Remick DG. Shorter duration of post-operative antibiotics for cecal ligation and puncture does not increase inflammation or mortality. PLoS One
2016; 11 9:e0163005.
61. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock
2002; 17 6:463–467.
62. Huet O, Ramsey D, Miljavec S, Jenney A, Aubron C, Aprico A, Stefanovic N, Balkau B, Head GA, de Haan JB, et al. Ensuring animal welfare while meeting scientific aims using a murine pneumonia model of septic shock. Shock
2013; 39 6:488–494.
63. Shrum B, Anantha RV, Xu SX, Donnelly M, Haeryfar SM, McCormick JK, Mele T. A robust scoring system to evaluate sepsis severity in an animal model. BMC Res Notes
64. Mella JR, Chiswick E, Stepien D, Moitra R, Duffy ER, Stucchi A, Remick D. Antagonism of the neurokinin-1 receptor improves survival in a mouse model of sepsis by decreasing inflammation and increasing early cardiovascular function. Crit Care Med
2017; 45 2:e213–e221.
65. Lewis AJ, Yuan D, Zhang X, Angus DC, Rosengart MR, Seymour CW. Use of biotelemetry to define physiology-based deterioration thresholds in a murine cecal ligation and puncture model of sepsis. Crit Care Med
2016; 44 6:e420–e431.
66. Chiswick EL, Mella JR, Bernardo J, Remick DG. Acute-phase deaths from murine polymicrobial sepsis are characterized by innate immune suppression rather than exhaustion. J Immunol
2015; 195 8:3793–3802.
67. Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock
2004; 21 2:121–125.
68. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med
2013; 369 9:840–851.
69. Traber DL. Expired nitric oxide and shock in higher order species. Crit Care Med
1999; 27 2:255–256.
70. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature
71. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol
1992; 148 9:2724–2730.
72. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA
73. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med
1996; 334 26:1697–1702.
74. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun
1999; 67 12:6603–6610.
75. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, Kuebler WM. Acute Lung Injury in Animals Study GAn official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol
2011; 44 5:725–738.